Skip to main content
Erschienen in: Diabetologia 6/2005

01.06.2005 | Article

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

verfasst von: E. Mannucci, L. Pala, S. Ciani, G. Bardini, A. Pezzatini, I. Sposato, F. Cremasco, A. Ognibene, C. M. Rotella

Erschienen in: Diabetologia | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypotheses

Chronic hyperglycaemia increases dipeptidyl peptidase IV (DPP-IV) activity in endothelial cells in vitro. The present study was designed to assess the effect of high glucose on circulating DPP-IV activity in patients with type 1 and type 2 diabetes.

Methods

Plasma DPP-IV activity was measured in 29 patients with type 1 diabetes and 29 age-, sex- and BMI-matched control subjects. We also assessed DPP-IV activity in 31 type 2 diabetic patients with HbA1c >8.5% and in plasma from matched groups of 31 newly diagnosed diabetic subjects with HbA1c <7.5%, 31 subjects with IGT and 62 subjects with NGT. In a further sample of 66 type 2 diabetic patients, a longitudinal study was also performed to evaluate variations in DPP-IV activity and HbA1c over 3 months.

Results

DPP-IV activity in type 1 diabetic patients was not significantly different from that in control subjects; however, a significant correlation between DPP-IV and HbA1c was observed in diabetic subjects (r=0.47; p<0.01). Type 2 diabetic patients with HbA1c >8.5% showed significantly (p<0.05) higher DPP-IV activity (mean±SD 27.7±7.1 U/l) than newly diagnosed diabetic patients and subjects with IGT (22.1±6.0 and 18.8±8.8 U/l, respectively). Variations in DPP-IV activity over 3 months in type 2 diabetic patients showed a significant positive correlation with variations in HbA1c (r=0.26; p<0.05).

Conclusions/interpretation

Chronic hyperglycaemia induces a significant increase in DPP-IV activity in type 1 and type 2 diabetes. This phenomenon could contribute to the reduction in circulating active glucagon-like peptide-1 and to the consequent postprandial hyperglycaemia in type 2 diabetic patients with poor metabolic control.
Literatur
1.
Zurück zum Zitat Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2:1300–1304CrossRefPubMed Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2:1300–1304CrossRefPubMed
2.
Zurück zum Zitat D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 95:2263–2266 D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 95:2263–2266
3.
Zurück zum Zitat Gutzwiller JP, Goke B, Drewe J et al (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81–86PubMed Gutzwiller JP, Goke B, Drewe J et al (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81–86PubMed
4.
Zurück zum Zitat Lugari R, Dell’Anna C, Ugolotti D et al (2000) Effect of nutrient ingestion on glucagon-like peptide-1 (7–36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 32:424–428PubMed Lugari R, Dell’Anna C, Ugolotti D et al (2000) Effect of nutrient ingestion on glucagon-like peptide-1 (7–36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 32:424–428PubMed
5.
Zurück zum Zitat Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 50:609–613PubMed Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 50:609–613PubMed
6.
Zurück zum Zitat Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide-1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMed Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide-1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMed
7.
Zurück zum Zitat Mannucci E, Ognibene A, Cremasco F et al (2000) Glucagon-like peptide-1 (GLP-1) and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 17:713–719CrossRefPubMed Mannucci E, Ognibene A, Cremasco F et al (2000) Glucagon-like peptide-1 (GLP-1) and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 17:713–719CrossRefPubMed
8.
Zurück zum Zitat Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723CrossRefPubMed Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723CrossRefPubMed
9.
Zurück zum Zitat Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M (1998) Exendin (9–39) is an antagonist of glucagon-like peptide-1 (7–36) amide in humans. J Clin Invest 101:1421–1430PubMed Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M (1998) Exendin (9–39) is an antagonist of glucagon-like peptide-1 (7–36) amide in humans. J Clin Invest 101:1421–1430PubMed
10.
Zurück zum Zitat Edwards CM, Todd JF, Mahmoudi M et al (1999) Glucagon-like peptide-1 has a physiological role in the control of post-prandial glucose in humans: studies with the antagonist exendin 9–39. Diabetes 48:86–93PubMed Edwards CM, Todd JF, Mahmoudi M et al (1999) Glucagon-like peptide-1 has a physiological role in the control of post-prandial glucose in humans: studies with the antagonist exendin 9–39. Diabetes 48:86–93PubMed
11.
Zurück zum Zitat Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7–36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7–36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed
12.
Zurück zum Zitat Berghofer P, Peterson RG, Schneider K, Fehmann HC, Goke B (1997) Incretin hormone expression in the gut of diabetic mice and rats. Metabolism 46:261–267CrossRefPubMed Berghofer P, Peterson RG, Schneider K, Fehmann HC, Goke B (1997) Incretin hormone expression in the gut of diabetic mice and rats. Metabolism 46:261–267CrossRefPubMed
13.
Zurück zum Zitat Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224CrossRefPubMed Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224CrossRefPubMed
14.
Zurück zum Zitat Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346–350CrossRefPubMed Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346–350CrossRefPubMed
15.
Zurück zum Zitat Pala L, Mannucci E, Pezzatini A et al (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28–31CrossRefPubMed Pala L, Mannucci E, Pezzatini A et al (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28–31CrossRefPubMed
16.
Zurück zum Zitat Mannucci E, Ognibene A, Sposato I et al (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 40:181–186CrossRefPubMed Mannucci E, Ognibene A, Sposato I et al (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 40:181–186CrossRefPubMed
17.
Zurück zum Zitat Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155–158CrossRefPubMed Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155–158CrossRefPubMed
18.
Zurück zum Zitat Augustyns K, Bal G, Thonus G et al (1999) The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 6:311–327PubMed Augustyns K, Bal G, Thonus G et al (1999) The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 6:311–327PubMed
19.
Zurück zum Zitat Mannucci E, Ognibene A, Cremasco F et al (2001) Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489–494PubMed Mannucci E, Ognibene A, Cremasco F et al (2001) Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489–494PubMed
20.
Zurück zum Zitat Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575–3581CrossRefPubMed Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575–3581CrossRefPubMed
21.
Zurück zum Zitat Rosenblum JF, Kozarich JW (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7:496–504CrossRefPubMed Rosenblum JF, Kozarich JW (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7:496–504CrossRefPubMed
22.
Zurück zum Zitat Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Flatt PR, O’Harte FP (2004) Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase-IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin(9–39). Metabolism 53:252–259CrossRefPubMed Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Flatt PR, O’Harte FP (2004) Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase-IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin(9–39). Metabolism 53:252–259CrossRefPubMed
23.
Zurück zum Zitat Wettergren A, Wojdemann M, Holst JJ (1998) The inhibitory effect of glucagon-like peptide-1 (7–36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9–36)amide. Peptides 19:877–892CrossRefPubMed Wettergren A, Wojdemann M, Holst JJ (1998) The inhibitory effect of glucagon-like peptide-1 (7–36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9–36)amide. Peptides 19:877–892CrossRefPubMed
Metadaten
Titel
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
verfasst von
E. Mannucci
L. Pala
S. Ciani
G. Bardini
A. Pezzatini
I. Sposato
F. Cremasco
A. Ognibene
C. M. Rotella
Publikationsdatum
01.06.2005
Erschienen in
Diabetologia / Ausgabe 6/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1749-8

Weitere Artikel der Ausgabe 6/2005

Diabetologia 6/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.